[The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
OBJECTIVE
To assess the efficacy of adenosine triphosphate (ATP) assay for chemosensitity testing of ovarian cancer cell line and to compare its predicting value with that of diphenyltetrazolium bromide (MTT) test.


METHODS
By using ATP assay and MTT test the cytotoxic effect of 7 anticancer drugs on ovarian cancer cell line AO were determined. The sensitivity and stability of ATP assay were compared with those of MTT test. The optimal time of exposure of the cells to the drugs before doing ATP chemosensitity assay is investigated.


RESULTS
(1) The results obtained by ATP assay correlate well with that by MTT test (r = 0.918 1). However, in 90% of the assay samples the cytotoxic effect of the chemotherapeutic agents on cancer cells detected by ATP assay was 10% or more stronger as compared with that determined by MTT test. The difference in sensitivity of the two assays was also demonstrated by the least number of living cells. A change of living cells of 60 per well could be detected by ATP assay while that detected by MTT test should be 200 per well. (2) By repeating the tests of a same batch of samples for 5 times, it revealed that the results obtained by ATP assay was more stable than MTT test. The difference between the sx- (standard error) of the two tests was significant (P < 0.05). (3) The optimal time of exposure of the cancer cells to the anticancer drugs for testing its chemosensitivity was 5 days.


CONCLUSIONS
The method of ATP assay for chemosensitivity test is simple and convenient with high sensitivity and stability. It may be used as a new in vitro chemosensitivity test in patients with ovarian cancer.
Shi
W
W
Tongji Hospital, Tongji Medical University, Wuhan.
Gu
M
M
Liang
L
L
D000255:Adenosine Triphosphate / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D001761:Bleomycin / Q000494:pharmacology*; D002945:Cisplatin / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000473:pathology*; D014407:Tumor Cells, Cultured / Q000378:metabolism; D014750:Vincristine / Q000494:pharmacology
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D001761:Bleomycin; D014750:Vincristine; D000255:Adenosine Triphosphate; D002945:Cisplatin